Pentoxifylline - instructions for use, dose, side effects, contraindications

Improves microcirculation and rheological properties of blood, has a vasodilating effect, blocks phosphodiesterase and promotes the accumulation of c-AMP in cells. Increases the elasticity of the erythrocyte membrane, reduces their adhesion, reduces platelet aggregation and blood viscosity.Adenoside blocks new receptors.

Pharmacokinetics:Metabolised by the liver. In the process of metabolism, several active metabolites are formed. The drug is excreted mainly through the kidneys in the form of metabolites. Less than 4% of the administered dose is excreted with feces. In patients with impaired liver function, the bioavailability of the drug increases and its half-life is prolonged.

Indications:

Violations of peripheral blood circulation. Ischemic cerebral stroke; disorders of blood circulation of the brain due to atherosclerosis, dyscirculatory encephalopathy. Trophic disorders of tissues and organs associated with thrombosis of arteries or veins, varicose veins, frostbite. Diabetic angiopathy. Disturbances of blood circulation in the vessels of the eyes, disturbance of the functions of the middle ear of the vascular nest accompanying deafness.

Contraindications:Hypersensitivity to pentoxifylline and similar drugs and substances from the group of xanthine derivatives, such as theophylline, caffeine, aminophylline or theobromine; acute myocardial infarction; massive bleeding; cerebral hemorrhage; massive hemorrhage in the retina; childhood; severe coronary or cerebralatherosclerosis; marked violations of the rhythm of the heart.

Pregnancy and lactation:

Treatment of pregnant pentoxifylline is contraindicated. The drug penetrates into breast milk, so lactating women should either refrain from breastfeeding, or they should be treated differently.

Dosing and Administration:

In patients with heart failure and liver and kidney disease, the drug should be used with caution.

The drug can be administered intravenously, intraarterially. Intravenously drip slowly in a dose of OD g in 250-500 ml isotonic sodium chloride solution or in 5% glucose solution (duration of administration - 90-180 minutes); intraarterially - first in a dose of 0.1 g in 20-50 ml of isotonic sodium chloride solution, and in the following days - 0.2-0.3 g in 30-50 ml of the solvent. Rate of administration: 0.1 g (5 ml of 2% solution of pentoxifylline) for 10 minutes.

Side effects:

During the introduction of the drug, reddening of the face, a burning sensation of the skin, a decrease in blood pressure, a feeling of heat, arrhythmias, pain in the chest, dizziness can be noted.

Overdose:

The first signs of an overdose: weakness, dizziness, tachycardia and lowering of blood pressure, development of drowsiness, fainting, agitation, convulsions.

Treatment is symptomatic: maintaining or restoring blood pressure, maintaining the function of breathing.

Interaction:

Pentoxifylline may enhance the effect of other drugs that affect the blood coagulation system (indirect and direct anticoagulants, thrombolytics); enhances the effect on the coagulation system of such drugs as cefamandol, cefape eazole, cefotetan, moxalactam, plikamycin, valproic acid; pentoxifylline may increase the effect of antihypertensive drugs, insulin, oral hypoglycemic drugs; cimetidine increases the stable concentration of pentoxifylline in the blood plasma, which can lead to an increase in the occurrence of side effects of the latter.

Joint appointment with other drugs, representatives of this group, can enhance the excitation of the central nervous system.

Special instructions:

The compatibility of the solution of pentoxifylline with the infusion solution should be checked in each specific case.

When carrying out intravenous infusions the patient should be in a prone position. The drug is well tolerated by patients at the recommended infusion rate and with injections.Care should be taken when intravenous and intra-atrial administration of the drug. The dose of the drug should be reduced for patients with low and unstable blood pressure. In elderly people, excretion of the drug is reduced, so a dose reduction may be required. The safety and effectiveness of pentoxifylline in children has not been studied.

Smoking can reduce the therapeutic effectiveness of the drug.

Effect on the ability to drive transp. cf. and fur:

Form release / dosage:

solution for injection in ampoules of 1 ml, 2 ml, 5 ml;

3, 5 or 10 ampoules in a pallet of high-density polyethylene; on 1,2,3,4 pallet in a carton box along with instructions for use.

Packaging:(1) - ampoules (10) - contour plastic packaging (pallets)
(1) - ampoules (3) - contour plastic packaging (pallets)
(1) - ampoules (5) - packings contour plastic (pallets)

Storage conditions:

Store at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use the product after the expiry date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:П N014549 / 03-2002

Date of registration:15.12.2008

The owner of the registration certificate:Shraya Life Senses Pvt. Ltd.Shraya Life Senses Pvt. Ltd. India

Manufacturer: & nbsp

SHREYA LIFE SCIENCES, Pvt.Ltd. India

Representation: & nbspSHREYA LIFE SENENSIZ Pvt.Ltd. SHREYA LIFE SENENSIZ Pvt.Ltd. India

Information update date: & nbsp25.08.2015

Illustrated instructions

Instructions

Pentoxifylline (Pentoxifylline)